Best Ocrevus (ocrelizumab) Clinics and Prices in Republic of Korea for Australians

Ocrevus treats relapsing forms of multiple sclerosis (RMS) in South Korea. It also treats primary progressive multiple sclerosis (PPMS) there. Specialist centres in Seoul use this B-cell therapy. It is given to adult patients with relapsing-remitting disease and active secondary progressive MS. It also effectively delays physical disability progression in those with PPMS.

• Clinical criteria: Specialists require a confirmed diagnosis and negative Hepatitis B screening results.
• Disease activity: Funding eligibility often depends on MRI progression or recent clinical relapses.
• Prior therapies: Clinicians usually recommend Ocrevus after two other disease-modifying treatments have failed.
• Administration modes: Providers offer both intravenous infusions and newer subcutaneous injections for patients.

Bookimed Expert Insight: Major Seoul hospitals like Severance Hospital and Ewha Womans University Medical Center dominate MS care. These JCI-accredited facilities handle massive patient volumes. Severance Hospital alone treats 1.6 million outpatients annually. This scale allows neurologists to manage complex immunosuppressive regimens. They do so with high safety standards and advanced monitoring.

Patient Consensus: Patients find the medical infrastructure in South Korea incredibly advanced and efficient. They appreciate the clear diagnostic protocols. They also value the supportive care from highly specialised neurology teams.

Specialists in the Republic of Korea administer Ocrevus (ocrelizumab) as an intravenous infusion. It treats multiple sclerosis. Healthcare professionals at JCI-accredited facilities, like Severance Hospital in Seoul, perform the procedure. The intravenous formulation is approved for patients with relapsing multiple sclerosis (RMS) and primary progressive forms.

• Infusion method: Doctors deliver the medication via an intravenous drip in a clinical theatre.
• Initial dose: Patients receive two 300mg infusions spaced exactly two weeks apart.
• Maintenance schedule: A single 600mg maintenance infusion follows every 6 months.
• Session duration: Each infusion session typically lasts 2 to 4 hours.
• Patient monitoring: Clinical staff monitor for infusion reactions during and after the procedure.

Bookimed Expert Insight: Major Seoul clinical centres like Severance Hospital manage over 1.6 million outpatients annually. This high volume means their neurology departments have deep experience managing infusion protocols. They often use premedication like corticosteroids so the 4-hour sessions remain comfortable and safe.

The Republic of Korea covers Ocrevus (ocrelizumab) via the National Health Insurance Service (NHIS). Both intravenous and subcutaneous forms are subsidised for Relapsing Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS). Registered foreign residents staying over 6 months are eligible for these government benefits.

• Eligible conditions: Coverage applies specifically to patients with RMS and PPMS diagnoses.
• Clinical requirements: Patients must provide specialist diagnosis and negative Hepatitis B screening.
• Treatment sequence: Insurance often covers Ocrevus as a second-line relapsing-remitting MS treatment.
• Residency rules: Foreigners registered for 6+ months access the same subsidies as citizens.

Bookimed Expert Insight: While NHIS provides coverage, the price for Ocrevus in Korea typically ranges from $18,200 to $23,400. Patients should consider visiting JCI-accredited centres like Severance Hospital. These major hubs manage 4,000,000 outpatients annually and have established protocols for administering complex biological medications.

Patient Consensus: Patients recommend contacting international centres at major Seoul hospitals to confirm specific clinical criteria. Australians often compare Korean options with the Pharmaceutical Benefits Scheme (PBS). This helps them find the best value.

Ocrevus treatment is available at major university hospitals in Seoul. These include Severance Hospital and Ewha Womans University Medical Center. Specialists administer this intravenous infusion twice a year for relapsing or primary progressive multiple sclerosis. They provide it at JCI-accredited facilities that follow international safety protocols.

• Clinic accreditation: Severance Hospital holds JCI and KOIHA certifications for high-standard care.
• Expert access: Major hospitals employ neurologists recognised as top multiple sclerosis experts.
• Hospital infrastructure: Large centres like Severance manage 1.6 million outpatients with imaging.
• Treatment cost: Infusions in Seoul typically cost between $18,200 and $23,400.

Bookimed Expert Insight: Data suggests that choosing a university hospital provides the most secure path for Ocrevus. These institutions, like Severance, maintain ongoing partnerships with global leaders like Johns Hopkins. This gives patients access to the latest international protocols and English-speaking specialists.

Patient Consensus: Patients find that bringing MRI scans on a physical CD speeds up the process. Most specialists in major Seoul hospitals speak English well and provide high-level care.